DexCom (NASDAQ:DXCM) Director Bridgette Heller Sells 1,012 Shares

DexCom, Inc. (NASDAQ:DXCM – Get Free Report) Director Bridgette Heller sold 1,012 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total value of $60,730.12. Following the sale, the director owned 25,007 shares in the company, valued at approximately $1,500,670.07. This trade represents a 3.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Price Performance

Shares of DexCom stock opened at $57.82 on Friday. The stock has a market cap of $22.31 billion, a price-to-earnings ratio of 24.71, a price-to-earnings-growth ratio of 1.01 and a beta of 1.40. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The stock has a 50 day moving average price of $63.69 and a 200-day moving average price of $65.92. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98.

Get DexCom alerts:

DexCom (NASDAQ:DXCM – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.09. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.DexCom’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.32 EPS. Equities analysts expect that DexCom, Inc. will post 2.56 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Trust Co. of Vermont boosted its position in DexCom by 14.8% in the 4th quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock valued at $74,000 after buying an additional 145 shares during the period. CVA Family Office LLC increased its position in shares of DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after acquiring an additional 147 shares during the period. V Square Quantitative Management LLC raised its stake in shares of DexCom by 1.8% during the first quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock valued at $604,000 after acquiring an additional 172 shares in the last quarter. Essex Financial Services Inc. boosted its holdings in shares of DexCom by 5.7% in the first quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock valued at $204,000 after purchasing an additional 175 shares during the period. Finally, IFP Advisors Inc boosted its holdings in shares of DexCom by 24.7% in the third quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock valued at $61,000 after purchasing an additional 178 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Benchmark assumed coverage on shares of DexCom in a report on Monday. They issued a “buy” rating and a $77.00 target price for the company. Sanford C. Bernstein set a $77.00 price target on shares of DexCom in a report on Friday, May 1st. Evercore raised shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price objective on the stock in a research report on Tuesday, March 24th. Weiss Ratings raised shares of DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, March 4th. Finally, Truist Financial reaffirmed a “buy” rating and set a $80.00 target price (down from $82.00) on shares of DexCom in a research note on Tuesday, February 17th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $83.22.

Get Our Latest Stock Report on DexCom

DexCom Company Profile

(Get Free Report)

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

Featured Stories

• Five stocks we like better than DexCom
• Aeluma’s Post-Earnings Dip Creates a Buying Opportunity
• Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs
• 2 Ways to Play the Big Pharma Patent Cliff
• YETI Rallies After Earnings Beat and Raised Outlook

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.